Latest data from the CARE-MS II extension study show that alemtuzumab (Lemtrada, Genzyme/Sanofi) has a durable effect on disability in multiple sclerosis (MS), with the mean Expanded Disability Status Scale (EDSS) score at 3 years still below that at baseline.<br><br>
These new data were presented in a poster at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) last week...... Read More - http://www.ms-uk.org/lemtrada
Alemtuzumab 3-year data show durable effect on MS disability
Alemtuzumab 3-year data show durable effect on MS disability
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1194 Views
-
Last post by Petr75
-
- 0 Replies
- 12181 Views
-
Last post by accordingnature495
-
- 0 Replies
- 5090 Views
-
Last post by NHE
-
- 0 Replies
- 1300 Views
-
Last post by NHE
-
- 4 Replies
- 1394 Views
-
Last post by Scott1
-
- 0 Replies
- 2019 Views
-
Last post by NHE
-
- 0 Replies
- 1662 Views
-
Last post by NHE
-
- 0 Replies
- 1418 Views
-
Last post by NHE